At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 104 enrolled
Drug / intervention
ABT-450/r/ABT-267 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Treatment-Naïve and Treatment-Experienced Asian Adults With GT1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis
In Brief
A Phase 3 clinical trial evaluating ABT-450/r/ABT-267, ABT-333, and 1 other intervention for Chronic Hepatitis C Virus (HCV). Completed, enrolled 104 participants.
Detailed Summary
This is a Phase 3, open-label, multicenter study evaluating the efficacy and safety of ABT-450/r/ ABT-267 and ABT-333 coadministered with RBV for 12 weeks in HCV genotype 1b, treatment naïve and Interferon (IFN) (alpha, beta or pegIFN) plus RBV treatment-experienced Asian adults with compensated cirrhosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C Virus (HCV)
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJul 2015
First PostedAug 2015
Primary CompletionSep 2016
Study CompletionMar 2017
TodayJul 2026
First PostedAug 7, 2015
Enrollment StartJul 20, 2015
Primary CompletionSep 29, 2016
Study CompletionMar 16, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 10.9 years ago
Interventions
ABT-450/r/ABT-267drug
Tablet
ABT-333drug
Tablet
ribavirindrug
Tablet